Skip to main content

Table 1 Correlation between TIL, TAM and clinicopathologic characteristics in the 401 gastric cancers

From: Tumor-infiltrating CD8+ T cells combined with tumor-associated CD68+ macrophages predict postoperative prognosis and adjuvant chemotherapy benefit in resected gastric cancer

Characteristics CD8+ TIL p value CD68+ TAM p value
Negative (%) Positive (%) Negative (%) Positive (%)
All cases 196 (48.6) 205 (51.1)   217 (54.1) 184 (45.9)  
Sex    0.596    
 Female 61 (31.1) 69 (33.7)   72 (33.2) 58 (31.5) 0.749
 Male 135 (68.9) 136 (68.3)   145 (66.8) 126 (68.5)  
Age (y)    0.915    0.668
 <65 134 (68.4) 139 (67.8)   150 (69.1) 123 (66.8)  
  ≥ 65 62 (31.6) 66 (32.2)   67 (30.9) 61 (33.2)  
Tumor location    0.805    0.330
 Proximal 58 (29.6) 59 (28.8)   68 (31.3) 49 (26.6)  
 Middle 30 (15.3) 39 (19.0)   37 (17.1) 32 (17.4)  
 Distal 96 (49.0) 95 (46.3)   103 (47.5) 88 (47.8)  
 Entire 12 (6.1) 12 (5.9)   9 (4.1) 15 (8.2)  
Tumor size (cm)    0.260    0.441
 <5 114 (58.2) 131 (63.9)   137 (63.1) 108 (58.7)  
  ≥ 5 82 (41.8) 74 (36.1)   80 (36.9) 76 (41.3)  
Differentiation    0.858    0.840
 Differentiated 83 (42.3) 85 (41.5)   92 (42.4) 76 (41.3)  
 Undifferentiated 113 (57.7) 120 (58.5)   125 (57.6) 108 (58.7)  
Lymphovascular invasion    0.044    0.130
 Absent 101 (51.5) 127 (62.0)   131 (60.4) 97 (52.7)  
 Present 95 (48.5) 78 (38.0)   86 (39.6) 87 (47.3)  
Tumor depth    0.158    0.225
 T1/2 75 (38.3) 93 (45.4)   97 (44.7) 71 (38.6)  
 T3/4 121 (61.7) 112 (54.6)   120 (55.3) 113 (61.4)  
Lymph node metastasis    0.014    0.919
 Absent 65 (33.2) 93 (45.4)   86 (39.6) 72 (39.1)  
 Present 131 (66.8) 112 (54.6)   131 (60.4) 112 (60.9)  
Pathological stage    0.123    0.561
 I 57 (29.1) 78 (38.0)   78 (35.9) 57 (31.0)  
 II 41 (20.9) 43 (21.0)   43 (19.8) 41 (22.3)  
 III 98 (50.0) 84 (41.0)   96 (44.2) 86 (46.7)  
Adjuvant chemotherapy    0.222    0.917
 Absent 65 (33.2) 80 (39.0)   79 (36.4) 66 (35.9)  
 Present 131 (66.8) 125 (61.0)   138 (63.6) 118 (64.1)